A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(17 sites)
China
Beijing Cancer Hospital, Beijing The First Affiliated Hospital of Bengbu Medical University, Bengbu XiangYa Hospital CentralSouth University, Changsha Fujian Cancer Hospital, Fuzhou Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou Cancer Hospital of Shandong First Medical University, Jinan Qilu Hospital of Shandong University, Jinan Yunnan Cancer Hospital, Kunming Guangxi Medical University Cancer Hospital, Nanning Fudan University Shanghai Cancer center, Shanghai The Obstetrics & Gynecology Hospital of Fudan University, Shanghai The Second Hospital of Hebei Medical University, Shijiazhuang Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Shananxi Provincial Cancer Hospital, Xi'an The First Affiliated Hospital of Xiamen University, Xiamen Yibin city second people's Hospital, Yibin Henan Cancer Hospital, Zhengzhou Age range
18 Years – 75 Years
Last updated January 2025